Human Molecular Genetics Advance Access published online on September 21, 2007
Human Molecular Genetics, doi:10.1093/hmg/ddm274
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer development
1 Cancer Genetics Program, Division of Hematology/Oncology, Department of Medicine, Northwestern University, Chicago, IL 60611 2 Robert H. Lurie Comprehensive Cancer Center, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611 3 Division of Environmental Health Sciences, School of Public Health, The Ohio State University, Columbus, OH 43210 4 Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210 5 Department of Pathology, Northwestern University, Chicago, IL 60611
* Correspondence to: Boris Pasche, M.D., Ph.D. Cancer Genetics Program Division of Hematology/Oncology, Department of Medicine Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine 676 N. St Clair Street, Suite 880 Chicago, IL 60611 Phone: 312-908-5284 Fax: 312-695-0319 Email: b-pasche{at}northwestern.edu
Received July 30, 2007; Revised August 27, 2007; Accepted September 14, 2007
TGFBR1*6A is a common hypomorphic variant of the type I TGF-ß receptor (TGFBR1), which transduces TGF-ß growth inhibitory signals less effectively than TGFBR1. Recent studies suggest that TGFBR1*6A confers a selective growth advantage to both normal appearing and cancerous epithelial cells in the presence of TGF-ß. We have previously shown that TGFBR1*6A is somatically acquired in head and neck and colon cancer. Using microdissected tissues we show that TGFBR1*6A is somatically acquired by stromal and epithelial cells adjacent to colorectal and head and neck tumors. Somatic acquisition of the TGFBR1*6A allele is not accompanied by acquisition of other tumor-specific mutations. Furthermore, lymphocytes located within the stroma or the normal appearing epithelium do not have evidence of TGFBR1*6A acquisition. The highest TGFBR1*6A/TGFBR1 allelic ratio is observed at the tumor's edge and traces of TGFBR1*6A are detected as far as 2 cm away from the tumor, which is suggestive of centrifugal spread of cells that harbor TGFBR1*6A. Assessment of CDH1 and CDH2 expression does not indicate epithelial-mesenchymal transformation. The results suggest that TGFBR1*6A somatic acquisition is a critical event in the early stages of cancer development that is associated with field cancerization. They also represent the first human report of somatically acquired altered stromal TGF-ß signaling during oncogenesis and the first report of a concordant mutation in the stromal and epithelial compartments in colon cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Eng, G. Leone, M. S. Orloff, and M. C. Ostrowski Genomic Alterations in Tumor Stroma Cancer Res., September 1, 2009; 69(17): 6759 - 6764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Eng Microenvironmental Protection in Diffuse Large-B-Cell Lymphoma N. Engl. J. Med., November 27, 2008; 359(22): 2379 - 2381. [Full Text] [PDF]
|
|
|
|
|
|
I. G. Campbell, W. Qiu, K. Polyak, I. Haviv, C. S. Zander, T. Soussi, G. Zalcman, E. Bergot, P. Hainaut, D. H. Roukos, et al. Breast-Cancer Stromal Cells with TP53 Mutations N. Engl. J. Med., April 10, 2008; 358(15): 1634 - 1636. [Full Text] [PDF]
|
|